Results 171 to 180 of about 7,521 (213)

HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg‐positive patients treated with nucleos(t)ide analogues

Journal of Viral Hepatitis, 2018
SummaryHBeAg seroconversion marks an important spontaneous change and treatment end‐point for HBeAg‐positive patients and is a pre‐requisite for HBsAg loss or functional cure. In this retrospective analysis, we aimed to identify predictors of seroconversion using serum quantitative HBsAg and HBcrAg, in HBeAg‐positive patients treated with nucleos(t)ide
B. Wang, I. Carey, M. Bruce, S. Montague, G. Dusheiko, K. Agarwal   +5 more
openaire   +3 more sources

Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion

Hepatology International, 2012
We investigated whether the combined presence and evolution of hepatitis B virus (HBV) mutant strains in the hepatitis B e antigen (HBeAg)-positive status can predict clinical outcomes after HBeAg seroconversion.One hundred and eighty-six patients with spontaneous HBeAg seroconversion were enrolled into this longitudinal study.
Chien-Hung, Chen, Chuan-Mo, Lee, Jing-Houng, Wang, Tsung-Hui, Hu, Chao-Hung, Hung, Chi-Sin, Changchien, Sheng-Nan, Lu   +6 more
openaire   +2 more sources

Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment

Antiviral Research, 2021
Antibody to hepatitis B core antigen (anti-HBc) is one of the most classical serological markers of HBV infection. This study aimed to investigate the association of serum anti-HBc and HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B (CHB) after antiviral treatment.
Xiang-An, Zhao, Jian, Wang, Jiacheng, Liu, Guangmei, Chen, Xiaomin, Yan, Bei, Jia, Yue, Yang, Yong, Liu, Da, Gu, Zhaoping, Zhang, Xiaoxing, Xiang, Rui, Huang, Chao, Wu   +12 more
openaire   +2 more sources

Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination

Infection, 1991
Acute hepatitis C virus superinfection followed by spontaneous hepatitis B e antigen seroconversion and hepatitis B surface antigen clearance in a patient with chronic type B hepatitis is described. The observations suggests that HCV may exert a suppressive effect on hepatitis B virus.
Y F, Liaw, S M, Lin, I S, Sheen, C M, Chu   +3 more
openaire   +2 more sources

Identification of Serum Cytokine Profiles Associated with HBeAg Seroconversion Following Antiviral Treatment Interruption

Viral Immunology, 2014
The major shortcoming of nucleos(t)ide analogue therapy for chronic hepatitis B (CHB) is the frequent requirement for indefinite therapy. Withdrawal of treatment can result in viral rebound with an alanine aminotransferase (ALT) flare leading to hepatic decompensation, while in others this can lead to hepatitis B e antigen (HBeAg) seroconversion.
Shilpa, Chokshi, Helen, Cooksley, Antonio, Riva, Sandra, Phillips, Roger, Williams, Anuj, Gaggar, Nikolai V, Naoumov   +6 more
openaire   +2 more sources

Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion

Liver International, 2010
HBeAg seroconversion, in association with undetectable levels of hepatitis B virus DNA as determined by polymerase chain reaction, is an important goal in the treatment of patients with HBeAg-positive chronic hepatitis B (CHB). Achievement of sustained HBeAg seroconversion at an early age (
openaire   +2 more sources

ASSESSMENT OF PATIENTS WITH THERAPY INDUCED HBEAG SEROCONVERSION: A REAL-LIFE EXPERIENCE

Acta Medica Mediterranea, 2022
<p style="text-align:justify;font-size:9px;font-family:Times;"><b><i>Objective:</i></b><i> We aimed to evaluate clinical and laboratory features of chronic hepatitis B virus (HBV) patients before and after the therapy-induced Hepatitis B envelope antigen (HBeAg) seroconversion.<span> </span></
openaire   +1 more source

Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation

Journal of Hepatology, 2002
Lamivudine-induced hepatitis B e antigen (HBeAg) seroconversion in patients with chronic hepatitis B was reported to be durable by several studies but controversy still exists. The aim of this study was to evaluate the durability of the responses of lamivudine treatment.Among 53 chronic hepatitis B patients who had acute exacerbation and had finished ...
Chuan-Mo, Lee, Guan-Yeow, Ong, Sheng-Nan, Lu, Jing-Houng, Wang, Chun-Ann, Liao, Hung-Da, Tung, Tsung-Ming, Chen, Chi-Sin, Changchien   +7 more
openaire   +2 more sources

Increase risk of HBeAg-negative chronic hepatitis B with older age at HBeAg seroconversion

2010
Background: Recent evidence suggests that delayed HBeAg seroconversion is associated with poorer outcome. We aim to determine the incidence of HBeAg-negative chronic hepatitis B (CHB) according to the age at which HBeAg seroconversion occurs. Methods: Chronic hepatitis B patients with natural HBeAg seroconversion and over 12 months follow-up after ...
Fung, JYY, Lai, CL, Wong, DKH, Yuen, JCH, Yuen, RMF   +4 more
openaire   +2 more sources

Profiles of HBV DNA, ALT and HBeAG status after stopping lamivudine in patients with HBeAg seroconversion

2010
AIM: To determine the virological and biochemical relapse rates in Chinese CHB patients with lamivudine-induced HBeAg seroconversion after stopping lamivudine therapy, and to identify significant viral or biochemical factors predictive of subsequent relapse.
Wong, DKH, Yuen, JCH, Tanaka, Y, Yuen, RMF, Mizokami, M, Fung, JYY, Lai, CL   +6 more
openaire   +2 more sources